Stem Cell Therapy for Diabetes

The treatment of patients with diabetes mellitus may greatly benefit from the use of undifferentiated or undeveloped cells. The developmental stages and transcription factors involved in this process have been defined by research on the capacity of human embryonic undifferentiated cells to segregate into islet cells. In any event, ethical considerations as well as the possibility for teratoma formation limit the clinical applications of human embryonic stem cells.

    Related Conference of Stem Cell Therapy for Diabetes

    January 11-12, 2024

    5th Global summit on Diabetes and Endocrinology

    Dubai, UAE
    January 11-12, 2024

    33rd International Diabetes and Healthcare Conference

    Dubai, UAE
    February 01-02, 2024

    30th International Conference on Human Metabolic Health- Diabetes, Obesity & Endocrinology

    Dubai, UAE
    February 08-09, 2024

    33rd European Diabetes Congress

    Paris, France
    March 14-15, 2024

    26th World Congress on Diabetes and Endocrine Disorders

    London, UK
    March 14-15, 2024

    7th Annual Meeting on Diabetes and Endocrinology

    London, UK
    March 25-26, 2024

    5th Annual Conference on Diabetes

    London, UK
    April 04-05, 2024

    19th International Conference on Endocrinology and Metabolic Disorders

    Madrid, Spain
    May 23-24, 2024

    35th International Congress on Prevention of Diabetes and Complications

    Zurich, Switzerland
    May 30-31, 2024

    22nd Global Conference on Diabetes, Endocrinology and Primary Healthcare

    Amsterdam, Netherlands
    June 27-28, 2024

    4th Annual Summit on Diabetes and Endocrinology

    London, UK

    Stem Cell Therapy for Diabetes Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in